MedTrace Logo

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

NCT01481402 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-07-16

No results posted yet for this study

Summary

Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

Conditions

Interventions

DRUG

Liothyronine

Liothyronine 40 microgram per day

DRUG

Liothyronine

3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)

Sponsors & Collaborators

  • Jens Faber

    lead OTHER

Principal Investigators

  • Jens Faber, MDSci · Herlev Hospital, Dept. of Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01481402 on ClinicalTrials.gov